A comprehensive view of Oral Medicines/Supplements. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Analysts on Enanta suing Pfizer over Covid pill Paxlovid: SVB Securities says it's unclear whether Enanta is in the right, noting patent dates might not prove who 'invented' technology first; RBC says it could take years for lawsuit to reach conclusion

Enanta files suit in US District Court against Pfizer seeking damages for copyright infringement related to Paxlovid nirmatrelvir, ritonavir tablets; Enanta applied for a patent for a coronavirus protease inhibitor in 2020 and received patent this month

Pfizer partners with MorphoSys, Incyte to evaluate combined therapy to treat diffuse large B-cell lymphoma, a type of blood cancer; drugs include Pfizer’s experimental TTI-622, Morphosys and Incyte’s Monjuvi tafasitamab-cxix, Revlimid lenalidomide

Pfizer completes acquisition of biopharmaceutical firm ReViral for US$525M; deal includes ReViral’s sisunatovir oral treatment for respiratory pathogen RSV, which affects 64 million people worldwide each year, causing 160,000 deaths

FDA approves Eli Lilly’s Olumiant oral treatment for alopecia areata, an autoimmune disorder that causes sudden hair loss; once-daily pill is first treatment of its kind and is available by prescription only

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count